Skip to Content

Ozempic Approval History

  • FDA approved: Yes (First approved December 5th, 2017)
  • Brand name: Ozempic
  • Generic name: semaglutide
  • Dosage form: Injection
  • Company: Novo Nordisk
  • Treatment for: Diabetes, Type 2

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) analog administered once-weekly for the treatment of adults with type 2 diabetes.

Development History and FDA Approval Process for Ozempic

Dec  5, 2017Approval Novo Nordisk Receives FDA Approval of Ozempic (semaglutide) Injection For the Treatment of Adults with Type 2 Diabetes
Oct 18, 2017Novo Nordisk Receives Positive 16-0 vote from FDA Advisory Committee in Favor of Approval for Semaglutide
Dec  5, 2016Novo Nordisk Files for Regulatory Approval of Once-Weekly Semaglutide with the FDA for the Treatment of Type 2 Diabetes
Apr 28, 2016Semaglutide significantly reduces the risk of major adverse cardiovascular events in the SUSTAIN 6 trial
Feb 23, 2016Novo Nordisk successfully completes fifth phase 3a trial with semaglutide in people with type 2 diabetes
Dec 17, 2015Novo Nordisk successfully completes fourth phase 3a trial with semaglutide in people with type 2 diabetes
Aug 26, 2015Novo Nordisk to Initiate Phase 3a Development of Oral Semaglutide, a Once-Daily Oral GLP-1 Analogue
Jul 10, 2015Novo Nordisk Successfully Completes First Phase 3a Trial with Semaglutide in People with Type 2 Diabetes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.